Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | MTOR | P42345 | 3/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LIPC | P11150 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380805 | 0.85 | CHRM2 (0.42) | TMEM97SIGMAR1APPCTSGHSP90AA1 | |
| SCHEMBL381330 | 0.84 | HDAC6 (0.42) | HDAC6HDAC3HDAC1TMEM97SIGMAR1 | |
| SCHEMBL379907 | 0.81 | HDAC6 (0.42) | HDAC6TMEM97SIGMAR1HTT | |
| SCHEMBL380775 | 0.79 | HDAC3 (0.46) | HDAC6HDAC3HDAC1 | |
| SCHEMBL767860 | 0.78 | HDAC1 (0.48) | HDAC6HDAC3HDAC1 | |
| SCHEMBL356822 | 0.72 | KMT2A (0.42) | PIK3CAMTOR | |
| SCHEMBL2993559 | 0.71 | HTT (0.56) | TMEM97SIGMAR1ACKR3HTTCHEK1 | |
| SCHEMBL21814958 | 0.71 | RAB9A (0.45) | HDAC6HDAC3HDAC1 | |
| SCHEMBL381759 | 0.70 | TSHR (0.33) | HDAC6HDAC3HDAC1APP | |
| SCHEMBL380427 | 0.70 | HDAC6 (0.42) | HDAC6HDAC3HDAC1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476253-B2 | Amide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | HDAC6 407/4885HDAC3 202/4885HDAC1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.